|
Observation period, days, median [range]
|
632 [153–2902]
|
785 [184–3278]
|
0.021
|
|
Age, years, median [range]
|
67 [38–89]
|
72 [34–88]
|
0.231
|
|
Sex (men/women), n
|
30/11
|
40/21
|
0.515
|
|
BMI in men, kg/m2, median [range]
|
23.5 [17.6–32.7]
|
23.5 [16.2–33.8]
|
0.972
|
|
BMI in women, kg/m2, median [range]
|
22.8 [16.0–34.7]
|
23.2 [17.1–37.5]
|
0.858
|
|
ΔL3 SMI in men, %, median [range]
|
−10.1 [−34.2– −4.7]
|
−0.8 [−4.3–14.2]
|
< 0.001
|
|
ΔL3 SMI in women, %, median [range]
|
−8.3 [−25.2– −5.3]
|
1.4 [−4.5–13.0]
|
< 0.001
|
|
Etiology (HBV/HCV/NBNC), n
|
4/22/15
|
7/28/26
|
0.744
|
|
ALT, U/L, median [range]
|
47 (10–243)
|
37 (9–166)
|
0.188
|
|
Total bilirubin, mg/dL, median [range]
|
1.1 [0.4–2.4]
|
0.9 [0.5–3.5]
|
0.423
|
|
Albumin, g/dL, median [range]
|
3.6 [2.1–4.7]
|
3.7 [2.0–4.9]
|
0.026
|
|
Platelet count, ×104/μL, median [range]
|
11.9 [3.4–80.9]
|
12.1 [2.2–27.1]
|
0.453
|
|
Child-Pugh classification (A/B), n
|
27/14
|
41/20
|
1.000
|
|
AFP, ng/mL, median [range]
|
54 [2.0–633,900]
|
14 [1.0–40,769]
|
0.009
|
|
TNM stage (I + II/III + IV), n
|
12/29
|
21/40
|
0.668
|
|
Maximum tumor diameter, mm, median [range]
|
50 [10–198]
|
28 [9–120]
|
0.009
|
|
Number of tumors (solitary/multiple), n
|
12/29
|
17/44
|
1.000
|
|
Treatment sessions between CT exams (1/≥ 2, sessions), n
|
24/17
|
35/26
|
1.000
|
|
mRECIST assessment (non-PD/PD), n
|
18/23
|
35/26
|
0.227
|
|
BCAA supplementation (presence/absence), n
|
30/11
|
42/19
|
0.665
|
